Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke - PubMed (original) (raw)

Clinical Trial

Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke

Jeffrey A Switzer et al. Stroke. 2011 Sep.

Abstract

Background and purpose: Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage.

Methods: The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group.

Results: Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019).

Conclusions: Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.

PubMed Disclaimer

Figures

Figure 1

Levels of MMP-9 over time in MINOS. (A) MMP-9 levels in tPA-treated and tPA-untreated subjects at each timepoint in MINOS.Box = 25 to 75% interquartile range; horizontal line = median; vertical lines = range. *p < 0.0083. (B) A representative zymogram from a MINOS patient showing MMP-9 over time.

Figure 2

Levels of MMP-9 in MINOS and comparison subjects at 24 hours. MMP-9 in tPA-treated and tPA-untreated MINOS and comparison subjects at 24 hours. Box = 25 to 75% interquartile range; horizontal line = median; vertical lines = range. *p < 0.0125.

Comment in

Letter by Lee regarding article, "Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute stroke".
Lee R. Lee R. Stroke. 2011 Oct;42(10):e566; author reply e567. doi: 10.1161/STROKEAHA.111.632869. Epub 2011 Sep 8. Stroke. 2011. PMID: 21903959 No abstract available.

Cited by

Matrix metalloproteinases and ADAMs in stroke.
Montaner J, Ramiro L, Simats A, Hernández-Guillamon M, Delgado P, Bustamante A, Rosell A. Montaner J, et al. Cell Mol Life Sci. 2019 Aug;76(16):3117-3140. doi: 10.1007/s00018-019-03175-5. Epub 2019 Jun 5. Cell Mol Life Sci. 2019. PMID: 31165904 Free PMC article. Review.
Minocycline and Magnesium As Neuroprotective Agents for Ischemic Stroke: A Systematic Review.
Ortiz JF, Ruxmohan S, Saxena A, Morillo Cox Á, Bashir F, Tambo W, Ghani MR, Moya G, Córdova I. Ortiz JF, et al. Cureus. 2020 Dec 28;12(12):e12339. doi: 10.7759/cureus.12339. Cureus. 2020. PMID: 33520535 Free PMC article. Review.
Communications Between Peripheral and the Brain-Resident Immune System in Neuronal Regeneration After Stroke.
Liu F, Cheng X, Zhong S, Liu C, Jolkkonen J, Zhang X, Liang Y, Liu Z, Zhao C. Liu F, et al. Front Immunol. 2020 Sep 18;11:1931. doi: 10.3389/fimmu.2020.01931. eCollection 2020. Front Immunol. 2020. PMID: 33042113 Free PMC article. Review.
Microglia-associated neuroinflammation is a potential therapeutic target for ischemic stroke.
Zhang W, Tian T, Gong SX, Huang WQ, Zhou QY, Wang AP, Tian Y. Zhang W, et al. Neural Regen Res. 2021 Jan;16(1):6-11. doi: 10.4103/1673-5374.286954. Neural Regen Res. 2021. PMID: 32788440 Free PMC article.
Effect of Reconstructive Procedures of the Extracranial Segment of the Carotid Arteries on Damage to the Blood-Brain Barrier.
Terlecki P, Przywara S, Terlecki K, Janczak D, Antkiewicz M, Zubilewicz T. Terlecki P, et al. Int J Environ Res Public Health. 2022 May 20;19(10):6210. doi: 10.3390/ijerph19106210. Int J Environ Res Public Health. 2022. PMID: 35627746 Free PMC article.

References

1. Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu M, Sorensen AG, Lo EH, Kelly PJ. Association between tpa therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology. 2006;66:1550–1555. - PubMed
1. Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, Gonzalez MA, Monasterio J. Matrix metalloproteinase expression after human cardioembolic stroke: Temporal profile and relation to neurological impairment. Stroke. 2001;32:1759–1766. - PubMed
1. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598–603. - PubMed
1. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke. 2008;39:3372–3377. - PMC - PubMed
1. Fagan SC, Waller JL, Nichols FT, Edwards DJ, Pettigrew LC, Clark WM, Hall CE, Switzer JA, Ergul A, Hess DC. Minocycline to improve neurologic outcome in stroke (minos): A dose-finding study. Stroke. 2010;41:2283–2287. - PMC - PubMed

Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke - PubMed (original) (raw)